← Eichor
Study identifier: NCT06756438 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.

Condition: Atopic Dermatitis · Eczema  ·  Sponsor: NAOS Les Laboratoires

PhaseNA
Planned participants88
Who can joinAll sexes, 3 Months to 12 Years
Healthy volunteersNo

About this study

Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities. The aim of this study is to assess the efficacy of a product for atopic skin versus a placebo. Primary objectives include assessing the number, the delay and severity of recurrences of atopic dermatitis (measured by the SCORAD score), and the evolution of symptoms such as dryness and pruritus. Secondary objectives include quality of life and quality of sleep and skin acceptability. The study protocol is a multicenter, double-blind, randomized clinical trial, in which participants receive either the study product or a placebo, while continuing their topical corticosteroid treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Wioleta MALINOWWSKA-KAKOL  ·  587320290  ·  wioleta.malinowska-kakol@cpt.eurofinseu.com

Always discuss trial participation with your own doctor first.

Locations (1)

EUROFINSGdansk, Poméranie, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06756438